Fri, 25 Mar 2011: 

stockpr_logo-site

FREE Daily Stock Alerts From Stock-PR.com

chartstockalert

 

Cal Dive International Inc. (NYSE:DVR) reported a net loss for fiscal 2010 of $315.8 million and $3.47 per diluted share. This compares to net income of $76.6 million and $.81 per diluted share for fiscal 2009. The 2010 net loss includes $302.5 million ($3.32 per diluted share) in non-cash impairment charges related to goodwill and four idle construction barges recorded during the third quarter. Excluding the impairment charges, the Company recorded a non-GAAP net loss of $13.3 million, or $.15 per diluted share for the year.

Cal Dive International, Inc., a marine contracting company, provides manned diving, pipelay and pipe burial, platform installation, and platform salvage services to the offshore oil and natural gas industry.

*************************

Power3 Medical Products, Inc. (PWRM.OB)

Thanks to Power3 Medical Products Inc. (PWRM.OB), people with Alzheimer’s may be able to say, thanks for the memory.

Power3 Medical Products recently made four poster presentations at the 2010 International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii. The leading proteomics company, which is focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, discussed NuroPro, Power3 Medical Products’ diagnostic test, and highlighted Power3 Medical Products’ Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” said Helen R. Park, MS, Chief Executive Officer of Power3 Medical Products, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”

“We are within striking distance of realizing an Alzheimer’s clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,” added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.

Alzheimer’s is one, among the common sort of dementia, an over-all term regarding loss of memory and various other intellectual abilities serious enough to interfere with routine daily life. Alzheimer’s condition is the reason for 50 to seventy per cent of dementia cases.

Alzheimer’s disease just isn’t an everyday aspect of increasing age, although the most significant identified risk factor is increasing age, and the most of individuals with Alzheimer’s are 65 and older. Alzheimer’s is just not a illness connected with senior years. As much as five percentage of people with the actual condition have early-onset Alzheimer’s (also called younger-onset), which frequently appears when someone is in an individual’s 40s or 50s.

Alzheimer’s declines ultimately. Alzheimer’s is a progressing sickness, in which symptoms gradually worsen over a period of time. Continuing, memory loss is minor, but with late-stage Alzheimer’s, people will not be able to hold on a conversation and respond to their natural environment. Alzheimer’s disease is the 6th major cause of loss of life in the USA. Some people that have Alzheimer’s live life an average of eight years after their indications come to be noticeable to other people, but survival can range from 3 to 20 years, based on maturity and various health conditions.

Power3 Medical Products applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical Products has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which Power3 Medical Products has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which Power3 Medical Products is currently engaged in Phase II clinical trials.

Discover more about PWRM at: www.power3medical.com

*************************

ING Prime Rate Trust (NYSE:PPR) declared 2.35 cents per share monthly dividend for the 28 days of February, paid on March 22, 2011 to shareholders of record on March 10, 2011. This represents the 274th consecutive monthly dividend since the Trust’s inception in May 1988.

ING Prime Rate Trust is a close ended fixed income mutual fund launched and managed by ING Investments, LLC. The fund is co managed by ING Investment Management Co. It invests in the fixed income markets of the United States and Canada.

*************************

http://pennyomega.com/img/clno.jpg CLNO, Cleantech Transit, Inc., CLNO.OB

Cleantech Transit Inc. (OTCBB:CLNO) disclosed additional details regarding its interest in a 500 Kilowatt biomass-generated power plant owned and operated by Phoenix Energy. The plant is fully constructed in Merced, California and is the first-of-its kind to receive an Authority to Construct permit from the San Joaquin Air Pollution Control District in California’s Central Valley as well as a use permit from Merced County.

Alex Holtermann, CEO of Cleantech, commented, “Full scale commercial operation of the plant is expected to be completed during the second quarter of 2011. Once the interconnection process is complete, the 500 Kilowatt plant can begin selling power to one of California’s largest utilities under a fixed price 15-year contract. This positions us to capitalize on numerous government incentives, including carbon credits, as well as help accelerate the adoption of renewable energies in the State of California.”

Presently, the plant is in its final stages of grid interconnection and is awaiting its final parallel test to the utility. After completing the interconnection process, the operator will begin a start-up and testing period. By the end of the testing phase, the first plant will have cost about $2.5 Million to $3.0 Million to construct with debt funding provided by the State of California and U.S. Endowment for Forestry and Communities. Equity for the project was provided by the parent company, Phoenix Energy.

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. Cleantech Transit has expanded its focus to invest directly in specific green projects that can maximize shareholder value. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech Transit has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project can generate shareholder returns as well benefit Cleantech Transit’s manufacturing clients worldwide.

*************************

CIBER, Inc. (NYSE:CBR) announced that Peter Cheesbrough is leaving CIBER after nine years with the company to pursue his interest in participating on other public company boards. CIBER named Claude Pumilia, a former Hewlett-Packard senior financial officer, as Chief Financial Officer effective April 4, 2011. Cheesbrough will continue at the company through the end of April working closely with Pumilia to ensure a smooth transition of duties and responsibilities.

CIBER, Inc. operates as a system integration and information technology (IT) services consulting company in the United States and internationally.

 

 

**********************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer). Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) anticipates receiving 2,000,000 shares of 144 restricted stocks from the company for 12 months of advertisement services for Cleantech Transit, Inc. (CLNO.OB). Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

**********************************************************

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

http://stock-pr.com/img/stock-pr_buscard.jpg

**********************************************************

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

 
Share/Bookmark